ArticleEmerging infectious diseases2026
Dual PCR-Sanger Sequencing Assay for Simultaneous sqle-Based Identification and Resistance Detection in Trichophyton Species.
Article in Emerging infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trichophyton fungal infections are common and increasingly complicated by terbinafine resistance. To support accurate molecular identification and resistance profiling, we provide a validated dataset of full-length squalene epoxidase (sqle) gene sequences from 493 Trichophyton isolates representing 18 species, addressing limited availability and misannotation of sqle sequences in public databases, particularly within the T. mentagrophytes complex. On the basis of that dataset, we designed 2 Sanger sequencing assays for simultaneously identifying species and detecting resistance-associated mutations. One targets the full-length gene, whereas the other amplifies a short region capturing all key resistance hotspots and species-specific single-nucleotide polymorphisms. The partial assay was evaluated on 66 clinical specimens and enabled clinically relevant species identification without internal transcribed spacer sequencing, supporting culture-independent detection. Of note, this approach differentiates T. indotineae from closely related species, overcoming a key diagnostic limitation and supporting clinical decision-making, surveillance, and management of resistant infections, despite limited resolution within certain species complexes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.